Evidence map›Paper›PMID 25523477›Full record

ArticlePediatric nephrology (Berlin, Germany)2015

Changes in urinary angiotensinogen posttreatment in pediatric IgA nephropathy patients.

Maki Urushihara, Takashi Nagai, Yukiko Kinoshita, Sato Nishiyama, Kenichi Suga, Natsuko Ozaki, Ariunbold Jamba, Shuji Kondo, Hiroyuki Kobori, Shoji Kagami

Open access · greenAbstract read
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Maki UrushiharaDepartment of Pediatrics, Institute of Health Biosciences, University of Tokushima Graduate School, Kuramoto-cho 3-18-15, Tokushima, 770-8503, Japan, urushihara@tokushima-u.ac.jp.
Takashi Nagai
Yukiko Kinoshita
Sato Nishiyama
Kenichi Suga
Natsuko Ozaki
Ariunbold Jamba
Shuji Kondo
Hiroyuki Kobori
Shoji Kagami
Tokushima University · JPKagawa University · JP

Funding

Intrarenal Augmentation of Angiotensinogen by Ang IIR01DK072408 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI NAVAR, LUIS GABRIEL · 2006 to 2010
$1.2M
NIDDK NIH HHS R01 DK072408
6 · The paper itself

Abstract

backgroundRecently, we demonstrated that urinary angiotensinogen (AGT) levels are increased and reflect intrarenal renin-angiotensin system (RAS) status in pediatric patients with chronic glomerulonephritis. Therefore, this study was performed to test the hypothesis that urinary AGT (UAGT) levels provide a specific index of intrarenal RAS status associated with RAS blockade treatment in pediatric IgA nephropathy (IgAN) patients.

methodsWe measured plasma and UAGT levels and urinary transforming growth factor beta (TGF-β) levels, after which we performed immunohistochemical analysis of AGT, angiotensin II (Ang II), and TGF-β in 24 pediatric IgAN patients treated with RAS blockades for 2 years. Paired tests were used to analyze the changes from baseline to study end.

resultsAlthough there was no change in plasma AGT levels, UAGT and TGF-β levels were significantly decreased after RAS blockade, which was accompanied by the expression levels of AGT, Ang II, and TGF-β, as well as the magnitude of glomerular injury. Baseline UAGT levels positively correlated with diastolic blood pressure, urinary protein levels, scores for mesangial hypercellularity, and the expression levels of AGT, Ang II, and TGF-β in renal tissues.

conclusionsThese data indicate that UAGT is a useful biomarker of intrarenal RAS activation, which is associated with glomerular injury during RAS blockade in pediatric IgAN patients.

Indexed as

AdolescentAngiotensin-Converting Enzyme InhibitorsAngiotensin IIAngiotensin II Type 1 Receptor BlockersAngiotensinogenBiomarkersBiopsyChildEnzyme-Linked Immunosorbent AssayFemaleGlomerulonephritis, IGAHumansImmunohistochemistryKidneyMalePredictive Value of TestsAGT protein, humanAngiotensin-Converting Enzyme InhibitorsAngiotensin IIAngiotensin II Type 1 Receptor BlockersAngiotensinogenBiomarkersTransforming Growth Factor beta

Identifiers

PMID25523477
PMCPMC4406790
OpenAlexW2027794278

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.